Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 12;13(11):4050.
doi: 10.3390/nu13114050.

AMPK Activity: A Primary Target for Diabetes Prevention with Therapeutic Phytochemicals

Min-Yu Chung  1 , Hyo-Kyoung Choi  1 , Jin-Taek Hwang  1   2
Affiliations
Review

AMPK Activity: A Primary Target for Diabetes Prevention with Therapeutic Phytochemicals

Min-Yu Chung et al. Nutrients. .

Abstract

Diabetes is a metabolic syndrome characterized by inadequate blood glucose control and is associated with reduced quality of life and various complications, significantly shortening life expectancy. Natural phytochemicals found in plants have been traditionally used as medicines for the prevention of chronic diseases including diabetes in East Asia since ancient times. Many of these phytochemicals have been characterized as having few side effects, and scientific research into the mechanisms of action responsible has accumulated mounting evidence for their efficacy. These compounds, which may help to prevent metabolic syndrome disorders including diabetes, act through relevant intracellular signaling pathways. In this review, we examine the anti-diabetic efficacy of several compounds and extracts derived from medicinal plants, with a focus on AMP-activated protein kinase (AMPK) activity.

Keywords: AMP-activated protein kinase; diabetes; ingredient; medicinal plants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Godoy-Matos A.F., Silva Junior W.S., Valerio C.M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 2020;12:60. doi: 10.1186/s13098-020-00570-y. - DOI - PMC - PubMed
    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. Alam S., Hasan M.K., Neaz S., Hussain N., Hossain M.F., Rahman T. Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. Diabetology. 2021;2:36–50. doi: 10.3390/diabetology2020004. - DOI
    1. Yazdanpanah S., Rabiee M., Tahriri M., Abdolrahim M., Rajab A., Jazayeri H.E., Tayebi L. Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review. Crit. Rev. Clin. Lab. Sci. 2017;54:219–232. doi: 10.1080/10408363.2017.1299684. - DOI - PubMed
    1. Tan S.Y., Mei Wong J.L., Sim Y.J., Wong S.S., Mohamed Elhassan S.A., Tan S.H., Ling Lim G.P., Rong Tay N.W., Annan N.C., Bhattamisra S.K., et al. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab. Syndr. 2019;13:364–372. doi: 10.1016/j.dsx.2018.10.008. - DOI - PubMed